Molecular Cancer

BMC

Journal websitePeer review: Peer review
Evaluation status available after sign-in

About the journal

Molecular Cancer is an open-access journal published by BMC in United Kingdom, publishing in english. It is listed in DOAJ and MEDLINE and PUBMED according to the sources read. Declared publication charge: 4,390 EUR. Declared review time at DOAJ: 16 weeks. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.

Basic facts

Publisher
BMC
ISSN
1476-4598
Country
United Kingdom
Languages
english
Access
Open access
Declared publication charge
4,390 EUR
Articles in DOAJ
3152
Declared review time
16 weeks
Declared peer-review model
peer_review

Index listings

  • DOAJ · 2003-04-22
  • MEDLINE · 2002-01-01
  • PUBMED · 2002-07-11
Indexing
DOAJ · MEDLINE · PUBMED
APC
4,390 EUR
Declared review time (DOAJ)
16 weeks — journal-declared only (not measured)
Activity (OpenAlex)
Active — latest works 2026
PublishLens list status
Shown after sign-in
Counts for promotion at your university?
Choose your university and rank below ↓

Methodology signals (dated facts from their sources)

Details of the evaluation under the published methodology are shown to signed-in users (free).

Create a free account to view the evaluation

Journal profile

Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.

Articles in DOAJ

3152

Most recent article

last month

Average review time (journal-declared via DOAJ)

16weeks

Works in OpenAlex

3967

Last recorded publication year

2026

Reported by OpenAlex in 2 of 3 sources (CC0 flags, not verified indexing)DOAJSciELOOpenAlex Core

h-index

290

i10-index

3334

From OpenAlex open data (CC0).

Editorial & policy13
Last DOAJ review date
2026-03-17
Added to DOAJ
2003-04-22
Declared plagiarism screening
Declared
Other fees beyond APC
No
Declared digital preservation
LOCKSSPMC
Observed digital preservation (Keepers registry)— snapshot 2026-09-21
CLOCKSSPortico
Editorial board
Official page ↗
Norwegian register (HK-dir)— 2027
Level 2 — top tier (~20% of the field's channels)
Open references deposited at Crossref
92%
ORCID iDs in current deposits
10%
Enrolled in Crossref Similarity Check
✓
Deposits licence metadata at Crossref
✓
APC waiver policy
View policy
Peer-review policy
View policy
Identity & continuity2
Source type
journal
NLM unique ID (PubMed)
101147698
Classification2

Subjects (DOAJ)

Medicine: Internal medicine: Neoplasms. Tumors. Oncology. Including cancer and carcinogens

LCC codes

RC254-282

Subject areas

  • Cancer-related molecular mechanisms research
  • Cancer-related molecular mechanisms research
  • MicroRNA in disease regulation
  • MicroRNA in disease regulation
  • Circular RNAs in diseases
  • Circular RNAs in diseases
  • Cancer Cells and Metastasis
  • Cancer Cells and Metastasis
Show all subjects (50)
  • RNA modifications and cancer
  • RNA modifications and cancer
  • Cancer, Hypoxia, and Metabolism
  • Cancer, Hypoxia, and Metabolism
  • Cancer Immunotherapy and Biomarkers
  • Cancer Immunotherapy and Biomarkers
  • Epigenetics and DNA Methylation
  • Epigenetics and DNA Methylation
  • Ferroptosis and cancer prognosis
  • Ferroptosis and cancer prognosis
  • Immune cells in cancer
  • Immune cells in cancer
  • Cancer-related Molecular Pathways
  • Cancer-related Molecular Pathways
  • Extracellular vesicles in disease
  • Extracellular vesicles in disease
  • Cancer Genomics and Diagnostics
  • Immunotherapy and Immune Responses
  • Cancer Genomics and Diagnostics
  • Immunotherapy and Immune Responses
  • Cell death mechanisms and regulation
  • Cell death mechanisms and regulation
  • Cancer-related gene regulation
  • Cancer-related gene regulation
  • Cancer Mechanisms and Therapy
  • Cancer Mechanisms and Therapy
  • RNA Research and Splicing
  • RNA Research and Splicing
  • Wnt/β-catenin signaling in development and cancer
  • Wnt/β-catenin signaling in development and cancer
  • Ubiquitin and proteasome pathways
  • Ubiquitin and proteasome pathways
  • PI3K/AKT/mTOR signaling in cancer
  • PI3K/AKT/mTOR signaling in cancer
  • Microtubule and mitosis dynamics
  • Microtubule and mitosis dynamics
  • CAR-T cell therapy research
  • Cytokine Signaling Pathways and Interactions
  • Cytokine Signaling Pathways and Interactions
  • CAR-T cell therapy research
  • Immune Cell Function and Interaction
  • Immune Cell Function and Interaction

Keywords (DOAJ)

  • oncology
  • tumour biology
  • cancer antigens

Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.

Loading community confirmations…
How do we evaluate?Publisher of this journal? Appeal a derived assessment or request a factual correction

The journal's record in other sources:Web of Science MJLDOAJ

Everything shown here is produced automatically from named sources (DOAJ, OpenAlex, Crossref, PubMed, the Norwegian register) as of its capture date, with no human editing. Facts appear as recorded at the source; derived scores (PCI, PTD, PublishLens score) follow a published methodology. Not a judgement on the journal, not an official accreditation, not advice.

Wrong items are corrected automatically by re-reading the source (24 h for daily sources, 7 days for weekly ones) with a dated change log, and each item links to its source record. PublishLens-derived assessments are contested through the appeals mechanism (15 working days). Appeals · Indicator guide

Norwegian register data: Kanalregisteret (HK-dir, Norway) — CC BY 4.0 / NLOD — adapted: level extracted per year · OASPA member list — CC BY

Last automated source read: